You are here: / / Ver-A-T1D Trial

Ver-A-T1D Study

Recruiting closed

A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preservation of beta-cell function (Ver-A- T1D)

Open to recruitment:

  • Southmead Hospital, Bristol
  • Addenbrooke’s Hospital, Cambridge
  • University Hospital of Wales, Cardiff
  • Queen Elizabeth Hospital, Birmingham
  • Bart’s Hospital, London
  • Royal Hallamshire Hospital, Sheffield
  • John Radcliffe Hospital, Oxford
  • Singleton Hospital, Swansea
  • Guy’s Hospital, London
  • Queens Medical Centre, Nottingham

Summary

Trial of an existing blood pressure medication in people with Type 1 diabetes aged 18-44 years and within 6 weeks of diagnosis.

Aim

Verapamil, a known blood pressure lowering drug, has been shown recently to protect and strengthen beta cells and slows down beta cell destruction in T1D. The trial will include 120 patients aged between 18 and 44 years, taking tablets for 1 year with an optional follow up visit at 2 years.The aim is to confirm the effect of 360mg Verapamil sustained release (SR) administered orally once daily (titrated over the first 3 months from 120 mg to 360 mg)

Eligibility to take part:

  1. Age between 18 and 44 years
  2. Diagnosed with type 1 diabetes in the last 6 weeks

If you are interested in taking part, please click the “Get Involved” button below:

Get Involved

What will I be asked to do?

After signing the informed consent, you will be asked to come in for a screening visit to check if you are eligible for the study. If you are eligible, you will attend for a randomisation visit where it will be decided by chance which study medication you will receive (active or dummy). This is followed by 7 treatment visits (at the clinic), accompanied by 3 phone calls (phone visits). The amount of time you will spend at the clinic at each visit may vary. This is because the tests and checks will differ at each visit.

Who is running this study?

Study Sponsor: Medical University of Graz, Medical University of Graz Department of Internal Medicine Auenbruggerplatz 15 A8036 Graz Austria

Chief Investigator: Prof. Thomas Pieber, MD

Medical University of Graz

Co-Chief Investigator/PI Lead for the UK: Prof. Colin Dayan, MA FRCP PhD

Cardiff University School of Medicine

Collaborator: Juvenile Diabetes Research Foundation (JDRF)

Site Locator